This reduces the chance of a chain reaction if one pack ignites
Strong national healthcare systems in Germany, the UK, and France support broad access and reimbursement for GLP-1 therapies
Ongoing risk-benefit assessment is essential
New research underway More trials are now starting to look at how GLP-1s might influence things like chronic inflammation or immunosuppression, both of which might contribute to cancer growth
doi: 10.3389/fped.2023.1212405 Received 26 April 2023 Accepted 03 July 2023 Published 27 July 2023 Volume 11 - 2023 Edited by Massimo Zeviani, University of Padua, Italy Reviewed by Carlo Fiore Viscomi, University of Padua, Italy Muhammad Ikram Ullah, Jouf University, Saudi Arabia Updates Copyright 2023 Wu, Jiao, Xia, Yan, Liu, Cao and Ma
Without knowing precisely what is being injected into the body, ensuring client safety becomes a significant challenge